| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $11.2M | — | +67.9% |
| SG&A Expense | $6.7M | — | +10.7% |
| Operating Income | -$17.8M | — | -42.2% |
| Pre-tax Income | -$17.0M | — | -66.0% |
| Income Tax | $0 | — | — |
| Net Income | -$17.0M | — | -66.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $94.1M | +615.2% | +345.0% |
| Current Assets | $160.1M | +115.3% | +248.7% |
| Total Assets | $225.6M | +49.5% | +176.3% |
| Current Liabilities | $15.7M | +90.0% | +69.2% |
| Total Liabilities | $27.4M | +34.9% | +22.3% |
| Stockholders' Equity | $198.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$13.9M | — | -35.2% |
| Investing Cash Flow | $6.0M | — | +16.6% |
| Financing Cash Flow | $89.0M | — | — |
| +234.5% |